


Davidson's Principles and Practice of Medicine



22 key points about the 22nd Edition

- 1. Every chapter has been revised in detail by experts in the field to bring it up to date, and subjected to rigorous editorial review. The result is a book which is not increased in length, but contains all of the important contemporary updates in medical practice, presented with the clarity and simplicity that is Davidson's trademark.
- 2. A simplified classification provides a clearer presentation of the 1350 boxes used throughout the book. Popular In Old Age, In Pregnancy, Emergency and Practice Point boxes are retained while the Evidence-Based Medicine boxes which ensure that readers are aware of innovations in practice have been updated with descriptions of new guidelines.







Antiperistaltic agents: hyoscine should be avoided in those


Glucagon is preferred if an antiperistaltic agent is needed.

with glaucoma and can also cause tachyarrhythmias.

in these individuals.









26.60 Multiple sclerosis in pregnancy

- Counselling: provision of pre-conception counselling is best practice.
- Relapse risk: endocrine effects on the immune system ensure that relapse risk drops during pregnancy.
- Disease-modifying drugs: risk of teratogenicity means that all disease-modifying drugs should ideally be stopped 6–8 wks before conception and recommenced after breastfeeding has stopped.
- Post-partum relapse rate: rebound of immune system activity means that the highest risk of relapse is in the first year after delivery.

3. New 'In Adolescence' boxes highlight the fact that many chronic disorders that begin in childhood go on to become the responsibility of physicians practising adult medicine. These boxes acknowledge the overlap 'transitional' phase and the key points for adult physicians when looking after young people.



19.40 Cystic fibrosis in adolescence

Issues for the patient:

Move to adult CF centre – loss of trusted paediatric team Feelings of being different from peers due to chronic illness

Demanding treatments that conflict with social and school life

Pressure to take responsibility for self-care Relationship/fertility concerns

Issues for the patient's parents:

Loss of control over patient's treatment – feeling excluded Loss of trusted paediatric team Need to develop trust in adult team Feelings of helplessness when adolescent rebels or will not take treatment

. Issues for the CF team:


Reluctance or refusal by patient to engage with transition Management of deterioration due to non-adherence Motivation of adolescents to self-care Provision of adolescent-friendly health-care environment




18.124 Congenital heart disease in adolescence

- Patients: a heterogeneous population with residual disease and sequelae that vary according to the underlying lesion and in severity; each patient must be assessed individually.
- Management plan: should be agreed with the patient and include a 'cardiac destination'.
- Risks of surgery: non-cardiac surgery, e.g. for associated congenital abnormalities, carries increased risks and needs to be planned, with careful pre-operative assessment. Risks include thrombosis, embolism from synthetic shunts or patches, and volume overload from fluid shifts. Operative approaches should address cosmetic concerns, e.g. abdominal generator implantation may be less unsightly.
- Exercise: patients with mild or repaired defects can undertake moderately vigorous exercise but those with complex defects, cyanosis, ventricular dysfunction or arrhythmias require specialist evaluation and individualised advice regarding exercise.
- Genetics: 10–15% have a genetic basis and this should be assessed to understand the impact it may have for the patient's own future children. A family history, genetic evaluation of syndromic versus non-syndromic disorders and, sometimes, cytogenetics are required.
- Education and employment: may be adversely affected and occupational activity levels need to be assessed.
- End of life: some adolescents with complex disorders may misperceive and think they have been cured; transition to adult services may be the first time they receive information about mortality. Expectations on life expectancy need to be managed and adolescents are often willing to engage with this and play a role in decision-making.

4. The very popular **Clinical Examination overviews** at the start of each of the systems-based chapters are retained, and have been refreshed with new images for the manikins on the left page and new examples of examination methods and interpretation on the right page.



5. Robert Britton, whose **artwork** has underpinned the clarity of illustrations in Davidson's over many editions, has designed all of the new and revised figures, ensuring their consistency of quality and style.



- **6.** The regular introduction of **new authors and editors** maintains the freshness of each new edition. Dr Ian Penman has joined the editorial team and 18 new authors have helped to bring the content right up to date.
- **7.** An **expanded International Advisory Board** now comprises 38 members from 16 different countries. Their systematic review of the 21st Edition produced important suggestions which were incorporated in chapter planning for the 22nd Edition.


Countries represented on the International Advisory Board:

- Australia
- Bangladesh
- Egypt
- Hong Kong
- India
- Japan
- Jordan
- Libya


- Malaysia
- New Zealand
- Pakistan
- Poland
- Saudi Arabia
- South Africa
- Sri Lanka
- Sweden




8. A new chapter on Therapeutics and Good Prescribing by Simon Maxwell provides a stronger emphasis on the underlying principles of Clinical Pharmacology and a more detailed description of the practicalities of drug prescribing. This recognises the central role of drug prescriptions in the practice of medicine, addresses recently documented deficiencies in prescribing skills of medical students and recent graduates, and helps readers to negotiate the increasingly complex polypharmacy that occurs in the ageing population.





9. A new chapter on Stroke
Medicine by Peter Langhorne
recognises the emergence of this
discipline as a specific medical subspecialty, and highlights the strong
evidence base for contemporary
therapy of stroke.




10. A new section on Obesity by John Wilding in the Environmental and Nutritional Factors in Disease chapter provides a practical guide to management of this highly prevalent problem, and new figures describe the increasing role of bariatric surgical procedures.








11. A new paradigm in cancer biology, "the ten hallmarks of cancer" is introduced in the Oncology chapter and eloquently describes the key mechanisms involved in cancer development and progression.






12. Management of elderly patients remains a 'horizontal theme' throughout the book, captured in the In Old Age boxes, but the introductory chapter on Ageing and Disease has been revised by new author Miles Witham, detailing the latest methods for assessing frailty, disability and rehabilitation needs.


13. The **HIV/AIDS** chapter has been extensively revised by Gary Maartens, whose extensive experience of the condition in South Africa is reflected in a highly accessible and practical chapter.










14. New algorithms for adult life support, the management of acute coronary syndrome and hypertension, and the latest in cardiac CT and MR imaging, ensure the **Cardiology** chapter reflects state-of-the-art knowledge for all doctors.











15. New authors of the **Diabetes** chapter, Rory McCrimmon and Ewan Pearson, have brought many practical guidelines to life in new illustrations and algorithms, conveying how all doctors should respond to this increasingly prevalent and resource-consuming disease.






- 16. New authors David Jones and Quentin Anstee have extensively updated the chapter on **Liver Disease** to reflect the rapidly evolving fields of viral hepatitis, fatty liver and transplantation. A new approach to the assessment of patients is presented, highlighting the importance of careful clinical evaluation in determining acute from chronic liver disease.
- 17. The Neurology chapter has been thoroughly updated by new authors John Paul Leach and Richard Davenport, including new practical guidance on the challenges of the clinical approach and localisation of lesions in neurology.
- 18. The chapter on **Skin Disease** has been extensively restructured and updated by new authors, Sally Ibbotson and Robert Dawe. New sections on photosensitive and photo-aggravated conditions and the approach to common skin problems are matched by over 25 new high quality photographs.








19. The chapter on **Kidney and Urinary Tract Disease** has been completely restructured to include a new examination section, an extensively revised section on presenting problems, and updated sections on diseases of the collecting system, prostate disease and tumours of the kidney and urinary tract.

20. The Rheumatology and Bone Disease chapter has been fully revised with new author lain McInnes to include an updated section on imaging which emphasises the increasing importance of musculoskeletal ultrasound and MRI scanning in clinical practice, information on new diagnostic criteria for rheumatoid arthritis and seronegative spondyloarthropathies and an extensively updated section on drug treatment which puts the role of different drugs in context, and includes information on the latest biological therapies that are available.



- **21**. **Biological therapies** are introduced in the Therapeutics chapter and their use is explained in the Immunology chapter and where relevant throughout the book. The emergence and rapid expansion of this group of therapies for inflammatory diseases and cancer represents one the most significant developments in medicine in the last decade.
- **22.** The revolution in medical genetics and the potential of ground-breaking cell-based therapies is reflected in an updated **Molecular and Genetic Mechanisms of Disease** chapter.

Cytokines

Cytokines are small soluble proteins that act as multipurpose chemical messengers. Examples are listed in Box 4.2. They are produced by cells involved in immune responses and by stromal tissue. More than 100 cytokines have been described, with overlapping, complex roles in intercellular communication. Their clinical importance is demonstrated by the efficacy of 'biological' therapies (often abbreviated to 'biologics') that target specific cytokines (pp. 1102 and 18).

PRINCIPLES OF CLINICAL PHARMACOLOGY

Prescribers need to understand what the drug does to the body (pharmacodynamics) and what the body does to the drug (pharmacokinetics) (Fig. 2.1). Although this chapter is focused on the most common drugs, which are synthetic small molecules, the same principles apply to the increasingly numerous 'biological' therapies (sometimes abbreviated to 'biologics') now in use, which include peptides, proteins, enzymes and monoclonal antibodies (p. 74).

RESEARCH FRONTIERS IN MOLECULAR MEDICINE

Gene therapy

Replacing or repairing mutated genes (gene therapy) is very difficult in humans. Retroviral-mediated ex vivo replacement of the defective gene in bone marrow cells for the treatment of severe combined immune deficiency syndrome (p. 80) has been partially successful. There have been two major problems with the clinical trials of virally delivered gene therapy conducted to date:

- The random integration of the retroviral DNA (which contains the replacement gene) into the genome has caused leukaemia in some treated children via activation of proto-oncogenes.
- A severe immune response to the viral vector may be induced. It has not yet been possible to use non-viral means to introduce sufficient numbers of copies of replacement genes to produce significant biological effects.

Other therapies for genetic disease include PTC124, a compound that can 'force' cells to read through a mutation that results in a premature termination codon in an ORF with the aim of producing a near-normal protein product. This therapeutic approach could be applied to any genetic disease caused by nonsense mutations.